Health & beauty
U.S. Venture Partners
U.S. Venture Partners (USVP) has helped build great companies for nearly three decades. Since its inception in 1981, USVP has invested more than $1.8 billion in more than 350 companies. Throughout, USVP's partners have worked diligently and consistently with early stage companies, many of which have become industry leaders.
The USVP team consists of accomplished venture investors, former CEOs, senior executives and technology company founders that span four generations of high-technology venture investing. This engenders a perspective on business cycles, "hot" market trends, technology evolution and revolution that is not present among all early-stage investors. Together, they have more than 150 years of operating experience and 100 years of investment expertise. Founding partner Bill Bowes, who has 50 years of venture investment experience, was also the founder of Amgen, a $70 billion pharmaceutical company.
Their investment interests include components, software, systems, services and life sciences. Areas of current focus include semiconductors, software as a service, networking solutions for storage, wireless data, the Internet version 2.0, biomedical devices and new drugs with profound social benefits.
They invest at a steady pace even during periods when technology investing is out of favor. They do so because they take a long view and expect most of their companies to take five years or more to become established and self-sustaining. The immediate economic environment at a company's beginning is not particularly relevant to its ultimate success or value. This approach resulted in 19 new deals in 2002, for example, 15 of which were first-round investments. USVP invested in a similar number of start-ups in 2003 (15) and 2004 (18). Since 1981, USVP has invested more than $1.8 billion in over 350 companies. Sixty-nine companies achieved IPO as of the end of 2004. Many others have realized positive merger outcomes.
Wallington Investments, Ltd., is a private venture group that funds early stage and growth companies. Its investments span several industries including telecom, green tech, biotech and internet 2.0 and several continents including North America, Europe and Asia.